CA-ESRI
6.10.2020 14:02:19 CEST | Business Wire | Press release
Esri , the global leader in location intelligence, today announced two major capabilities in Site Scan for ArcGIS that will enable governments and critical infrastructure organizations to meet hardware and software regulations in the US and Europe. Through an established partnership with Auterion, creator of the most widely used open-source drone autopilot operating system, security-conscious US organizations will be able to use Site Scan, Esri's unmanned aerial systems flight planning and processing solution, to plan and execute missions with the trusted and secure Freefly Astro drone, powered by Auterion. Additionally, for organizations in Europe with data sovereignty requirements, a new and fully independent instance of Site Scan for ArcGIS has been deployed to European servers, ensuring that organizational data resides within the region.
Site Scan for ArcGIS is used by organizations that require drone imagery for visual inspections, site monitoring, asset management, and situational awareness. It's an all-in-one, cloud-based drone mapping solution for managing fleets and collecting, processing, analyzing, and sharing data products. Industries using this solution include architecture, engineering, construction, natural resources, infrastructure, and government. Core capabilities in Site Scan—such as scalability, collaboration, time saving, and now enhanced security functionality—provide value to customers.
The US government has recently issued a growing number of advisory warnings and bans on the use of drones that pose security risks. These precautions have adversely impacted federal agencies and private firms that manage critical infrastructure, causing them to adopt incongruous drone data capturing and processing workflows that consist of multiple vendor solutions. Esri can now offer these agencies a single, end-to-end drone solution that integrates Freefly Astro, using US Department of Defense-approved Blue sUAS software architecture from Auterion, and is fully supported by Site Scan.
"Our expertise in providing an enterprise drone platform based on open-source software enabled us to meet the needs of the US government and governments worldwide," said Dave Sharpin, CEO, Auterion Government Solutions. "We are very excited to partner with Esri and provide [its] users with our groundbreaking technology."
By law within Europe, data from publicly funded or critical infrastructure projects cannot leave the European Union (EU). To enable a scalable drone workflow, Site Scan for ArcGIS has been deployed to a server cluster in Ireland. European customers that require their data not be transmitted outside the region can now leverage this server cluster to meet project requirements.
"The relationship we have established with Auterion is key in being able to offer high-quality, secure drone software to our US customers looking to take advantage of our advanced, secure, drone-based imagery collection and management platform," said Richard Cooke, Esri director of imagery and remote sensing. "Additionally, through the development of the EU deployment, an even wider range of customers located in Europe will be able to maintain their data and data processing locally."
The Freefly Astro and Site Scan integration will be available for customers by December 2020. The European deployment of Site Scan is available today. To learn more about the new integration of Site Scan with the Freefly Astro drone or about the EU deployment of Site Scan, contact the Esri sales team at esri.com/en-us/arcgis/products/site-scan-for-arcgis/overview#contactsales .
About Auterion
Auterion provides enterprise and government with an ecosystem of software-defined drones, payloads, and third-party applications within a single easy to use platform based on open-source standards.
With 50+ employees across offices in California and Switzerland, Auterion has raised $25M in venture-backed funding from investors such as Lakestar, Mosaic Ventures, Costanoa Ventures, and Tectonic Ventures. The company's global customer base includes GE Aviation, Quantum Systems, Freefly Systems, Avy, and the U.S. Government. Learn more at www.auterion.com .
Twitter: @auterion
LinkedIn: https://www.linkedin.com/company/auterion/
Facebook: https://www.facebook.com/auterion/
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping helps customers unlock the full potential of data to improve operational and business results. Founded in 1969, Esri software is deployed in more than 350,000 organizations including 90 of the Fortune 100 companies, all 50 state governments, more than half of all counties (large and small), and 87 of the Forbes Top 100 Colleges in the U.S., as well as all 15 Executive Departments of the U.S. Government and dozens of independent agencies. With its pioneering commitment to geospatial information technology, Esri engineers the most advanced solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2020 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005312/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom